Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).

Abstract

Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen. A 6-month, cluster-randomized, open-label, multicenter, crossover trial was conducted to test the preference of Japanese patients with osteoporosis for monthly bisphosphonate versus weekly bisphosphonate. One hundred and forty-seven patients (postmenopausal women and men) with primary osteoporosis were recruited at eight outpatient clinics. The clinics were randomized into two groups according to the dosing protocol-monthly minodronate followed by weekly alendronate or risedronate for a total of 24 weeks, or weekly alendronate or risedronate followed by monthly minodronate for 24 weeks. Patient preference for either the monthly or weekly bisphosphonate regimen was evaluated using a preference questionnaire. One hundred and fifteen patients (78.2 %) who completed the trial were processed for the analyses. Significantly more patients preferred the monthly bisphosphonate regimen (65.2 %) than the weekly bisphosphonate regimen (15.7 %) (P = 0.007). 'Dosing schedule fits lifestyle better' was the most common reason given for the patient preference for both the monthly (32.0 %) and weekly bisphosphonate (33.3 %) regimens. Significantly more patients found the monthly bisphosphonate regimen to be more convenient (73.0 %) than the weekly bisphosphonate regimen (13.9 %) (P < 0.0001). The safety profiles of the two regimens were similar. The present trial demonstrated a strong patient preference for and the convenience of the monthly bisphosphonate regimen over the weekly bisphosphonate regimen in Japanese patients with osteoporosis.

• Authors: Jun Iwamoto, Hiroya Okano, Takefumi Furuya, Tomohiko Urano, Masaichi Hasegawa, Hisashi Hirabayashi, Takami Kumakubo, Kazuya Makita
• Journal: Journal of bone and mineral metabolism (J Bone Miner Metab) Vol. 34 Issue 2 Pg. 201-8 (Mar 2016) ISSN: 1435-5604 [Electronic] Japan
• PMID: 25794468 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Diphosphonates
• Imidazoles
• YM 529
• Risedronic Acid
• Alendronate

Topics

• Aged
• Aged, 80 and over
• Alendronate (administration & dosage, adverse effects, therapeutic use)
• Cross-Over Studies
• Demography
• Diphosphonates (administration & dosage, adverse effects, therapeutic use)
• Drug Administration Schedule
• Female
• Humans
• Imidazoles (administration & dosage, adverse effects, therapeutic use)
• Male
• Middle Aged
• Osteoporosis (drug therapy)
• Patient Preference
• Risedronic Acid (administration & dosage, adverse effects, therapeutic use)